Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Pitavastatin for Prevention of Cardiovascular Events in HIV-1 Infected Individuals
2018-001285-41Phase 3Active
- Sponsor
- NEAT ID Foundation
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) and cardiac morbidity comparing Pitavastatin with Placebo / Control (2 arms). Primary endpoint: Major adverse cardiovascular events (MACE). Started Oct 2018; status: active.
02
Drugs
pitavastatin
03
Conditions
human immunodeficiency virus infection (HIV)cardiac morbidity
Beyond the preview
Go deeper on 2018-001285-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001285-41.